The Aesthetic Guide May/June 2025 Issue
Spotlight on Innovation - New Players in the Neurotoxin Market
As the U.S. neurotoxin marketplace continues to grow more crowded, innovation isn't just about new formulations— it's also about the tools and technologies enhancing how those products are delivered. Here are two recent entrants making waves
LETYBO (LETIBOTULINUMTOXINA)
The latest FDA-approved aesthetic injectable neurotoxin, Letybo® (Hugel, Inc.; Gangwon-do, Republic of Korea), is the first Korean-made neuromodulator available in the U.S. through a partnership with BENEV Company, Inc. (Mission Viejo, Calif.). According to the manufacturer, it is the most-used neurotoxin in South Korea and is approved in more than 65 countries. FDA-approved to treat glabellar lines, its clinical standout feature includes a fast onset: 24% of patients report noticeable results as early as day one, with the majority (75%) seeing visible improvement by day three!
NavaClick is designed to increase patient comfort compared to traditional syringes
NAVACLICK INJECTION SYSTEM
Designed to upgrade the neurotoxin injection experience, the NavaClick™ Injection System (Lineage Biomedical, Stuart, Fla.) is a novel syringe platform engineered for precision, comfort and efficiency.
According to the company, its ultra-sharp needle maintains tip integrity longer than standard syringes, reducing the number of syringes needed per treatment. In a just-released IRB study, over 91% of patients experienced no bruising and reported less pain compared to past injections. Clinician feedback also pointed to greater accuracy in site and dose delivery, streamlined prep, improved outcomes and reduced product waste.